Study of ranolazine to prevent heart muscle damage after a heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a medication called ranolazine can help prevent damage to tiny blood vessels in the heart after a certain type of heart attack (STEMI). You may be eligible if you recently had this kind of heart attack and had a successful procedure to open a blocked artery, but still have other blockages that can be treated with stents.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You recently had a specific type of major heart attack (called STEMI) and a procedure to open the main blocked artery succeeded
- You have at least one other narrowed heart artery that can be treated with a stent
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control
- You do not have severe kidney or liver disease
- You are not taking certain medicines that can interact with ranolazine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests treatments for small blood vessel damage after a major heart attack (STEMI). If you have had a heart attack and are receiving a stent, this study may help improve recovery by targeting microvascular injury.
This trial tests a new drug given shortly after a first heart attack to see if it can reduce heart damage when blood flow is restored. It is for patients having a specific type of heart attack (STEMI) and getting a procedure to open the blocked artery within 6 hours of symptoms starting.
This trial tests whether a low-dose clot-busting medicine placed into the heart artery after a primary stent can improve outcomes in people with a certain type of heart attack. It also involves short hospital follow-ups and a heart MRI to look at how the heart is recovering.
This trial tests a new medicine called RTP-026 for people having a serious heart attack (STEMI). It looks at whether the medicine is safe and helps the heart recover better when given along with the standard procedure to open the blocked artery.
This trial tests a heart medication (a cardio-selective beta-blocker) given during a heart attack to see if it reduces damage to the heart muscle. It might help people having their first heart attack who are treated quickly with angioplasty (a procedure to open blocked arteries).
This trial studies whether adding a special heart “reset” step (ischemic postconditioning) and using an imaging guide during the emergency procedure can improve outcomes for people having a STEMI heart attack. It’s meant to optimize treatment when a blocked heart artery is being opened.
Hear when a new STEMI (ST Elevation MI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.